Cellectis (CLLS) Gross Profit Growth (1y) (2016 - 2023)
Powered by 
Analysis
Cellectis (CLLS) Gross Profit Growth (1y) (2016 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 11.24% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 15.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 63.51% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 126.09% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 33.01% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 57.16% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 351.57% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1,392.86% |
| Sep 30, 2023 | -10.42% |
| Jun 30, 2023 | -87.42% |
| Mar 31, 2023 | -709.38% |
| Dec 31, 2022 | 168.85% |
| Sep 30, 2022 | 78.69% |
| Jun 30, 2022 | 269.20% |
| Mar 31, 2022 | 101.37% |
| Dec 31, 2021 | 98.78% |
| Sep 30, 2021 | 45.09% |
| Jun 30, 2021 | 80.25% |
| Mar 31, 2021 | -105.15% |
| Dec 31, 2020 | -306.43% |
| Sep 30, 2020 | -138.79% |
| Jun 30, 2020 | -968.55% |
| Mar 31, 2020 | 10,017.33% |
| Dec 31, 2019 | -595.56% |
| Sep 30, 2019 | 11,034.21% |
| Jun 30, 2019 | -92.49% |
| Mar 31, 2019 | -91.76% |